Erthang, Diagnocure went to 6 canadian dollars on the back of the license deal and has since remained above 4. Right now we a trading at a discount of 80% to their market cap(they have approximately the same number of shares). They have a much larger amount of cash, and some revenues (still loss making though) and they are listed on a proper exchange.
But our technology is much better and has much larger revenue and earnings potential. One of the great things about RECAF is that it is extreemely specific and that makes it great for mass screening. Mass screening means a lot more revenue potential. With RECAF you need only sacrifice a very little bit of sensitivity for close to 100% specificity, by changing the cut-off level.
And of course a company like Diagnocure is going to spend a fortune per cancer type they want to develope an assay for, whereas we just use the same technology each time. That will save us a bulk of money and time. Add to that imaging and later on therapy.
If this one goes through we will win big time.
News 
Market Data 
Discover 
